5-HT3 receptor blocking properties of the antiparkinsonian agent, talipexole-Reference-Cited by-同舟云学术

5-HT3 receptor blocking properties of the antiparkinsonian agent, talipexole

Published:1996-07 Issue:5 Volume:27 Page:779-785
ISSN:0306-3623
Container-title:General Pharmacology: The Vascular System
language:en
Short-container-title:General Pharmacology: The Vascular System

Author:

Nishio Hiroaki,Kohno Yasuko,Fujii Akiko,Negishi Yuuji,Inoue Atsuko,Nakata Yoshihiro

Publisher

Elsevier BV

Subject

Pharmacology

Reference27 articles.

1. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity;Andrews;Can. J. Physiol. Pharmac.,1990

2. The 5-hydroxytryptamine receptor antagonist as antiemetics: preclinical evaluation and mechanism of action;Andrews;Eur. J. Cancer,1993

3. Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats;Amt;Pharmac. Toxicol.,1988

4. Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle from guinea-pig ileum;Buchheit;Naunyn-Schmiedeberg's Arch. Pharmac.,1985

5. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction;Cheng;Biochem. Pharmac.,1973

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tannic acid acts as an agonist of the dopamine D2L receptor, regulates immune responses, and ameliorates experimentally induced colitis in mice;Brain, Behavior, & Immunity - Health;2020-05

2. The serotonergic system in Parkinson's disease;Progress in Neurobiology;2011-10

3. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders;Progress in Brain Research;2008

4. Effects of Talipexole on Contraversive Rotation and Functional Impairment in MPTP-Induced Chronic Hemiparkinsonian Monkeys;Japanese Journal of Pharmacology;1998

5. Talipexole;CNS Drugs;1997-05